Drug Profile
Tapinarof - Beijing Wenfeng Tianji Pharmaceuticals/Dermavant Sciences/Japan Tobacco/Torii Pharmaceuticals
Alternative Names: Benvitimod; DHPS; DMVT 505; GSK-2894512; VTAMA; WBI-1001; XinbikeLatest Information Update: 02 May 2024
Price :
$50
*
At a glance
- Originator Welichem Biotech
- Developer Beijing Wenfeng Tianji Pharmaceuticals; Dermavant Sciences; Japan Tobacco; Torii Pharmaceutical; Welichem Biotech
- Class Anti-inflammatories; Antipsoriatics; Nonsteroidal anti-inflammatories; Resorcinols; Skin disorder therapies; Small molecules; Stilbenes
- Mechanism of Action Aryl hydrocarbon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Plaque psoriasis
- Preregistration Atopic dermatitis
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 29 Apr 2024 FDA assigns PDUFA action date of the fourth quarter of 2024 for tapinarof for Atopic dermatitis (In adolescents, In adults, In children, In the elderly) (Topical)
- 29 Apr 2024 US FDA accepts sNDA for tapinarof for Atopic dermatitis (In adolescents, In adults, In children, In the elderly) for review
- 07 Mar 2024 Dermavant Sciences completes a Phase-III clinical trials in Atopic dermatitis (In adolescents, In children, In adults, In the elderly) in Canada, USA (Topical) (NCT05142774)